Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of HM15275 in Healthy and Obese Subjects
NCT06481098Phase 1Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- May 2024
- Primary completion
- May 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing HM15275 with Placebo (2 arms). Primary endpoint: Safety and Tolerability at Day 57. Started May 2024; status: completed.
02
Drugs
efocipegtrutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06481098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06481098.